In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab. This study concluded that achieving minimal residual disease response leads to better outcomes for...
Read MoreLeukemia Posts on Medivizor
My Oncologist Doesn’t Believe Food Is Necessary
By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...
Read MoreLong-term safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia
In a nutshell This study aimed to investigate if first-line ibrutinib treatment was safe and effective in the long-term for patients with chronic lymphocytic leukemia. This study concluded that single-agent ibrutinib provided good outcomes for patients when compared to the standard treatment chlorambucil in...
Read MoreEvaluating measurable residual disease at myeloablative allogenic transplantation in patients with acute lymphoblastic leukemia
In a nutshell This study aimed to investigate if measurable residual disease (MRD) before transplant in patients with acute lymphoblastic leukemia (ALL) is associated with different outcomes in patients undergoing myeloablative total body irradiation (TBI)-based and chemotherapy (CT)-based conditioning. This study concluded that...
Read MoreOutcomes for patients with acute myeloid leukemia who receive ex vivo T cell-depleted hematopoietic stem cell transplantation
In a nutshell This study aimed to investigate the outcomes of patients with acute myeloid leukemia after ex vivo T cell-depleted allogeneic hemopoietic stem cell transplant. This study concluded that the outcomes for these patients compare favorably to an unmodified transplant and that the modified transplant leads to lower rates of...
Read MoreBlinatumomab compared to standard of care treatment for patients with acute lymphoblastic leukemia
In a nutshell This study aimed to compare outcomes of blinatumomab treatment and standard of care treatment for patients with relapsed/unresponsive Philadelphia chromosome-positive acute lymphoblastic leukemia. This study concluded that blinatumomab is a more suitable treatment for these patients than standard of care...
Read MoreWhat factors can predict the success of stem cell transplantation?
In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...
Read MoreIbrutinib, fludarabine, cyclophosphamide and rituximab for treating chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the combination of ibrutinib with fludarabine, cyclophosphamide, and rituximab (FCR) as a frontline treatment in young, fit patients with chronic lymphocytic leukemia. This study concluded that this combination is promising as a...
Read MoreStopping dasatinib treatment in patients with chronic myeloid leukemia and stable deep molecular response
In a nutshell This study aimed to investigate treatment-free remission after dasatinib treatment in patients with chronic-phase chronic myeloid leukemia. This study concluded that it is possible to stop dasatinib treatment in these patients once they have achieved a deep molecular response. Some...
Read MorePonatinib treatment for leukemia – expert recommendation consensus
In a nutshell This review aimed to look at ponatinib treatment for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia with a focus on cardiovascular management. This review concluded that ponatinib can lead to increased cardiovascular...
Read MoreThe effect of uric acid levels on the outcomes of patients having an allogeneic stem cell transplant
In a nutshell This study aimed to investigate the association of uric acid levels before a stem cell transplant and patient outcomes. This study concluded that high uric acid levels before the transplant led to increased mortality. Some background Uric acid is a product of metabolic breakdown and is a normal component of urine. It can also be a...
Read MoreLate anemia in elderly patients with newly diagnosed chronic myeloid leukemia treated with imatinib
In a nutshell This study aimed to investigate the occurrence of late chronic anemia in older patients with chronic lymphocytic leukemia treated with imatinib. This study concluded that late chronic anemia is common in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI)....
Read More
